drugset / Trial / NCT05290506
Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus
Non-randomizedSingle-groupOpen-labelTreatment
Summary
There are studies that suggest glycemic response to incretin-based therapies differs between Asians and Caucasians, whereby Asians have better response compared to Caucasians. Hence, the therapeutic response could also be augmented by difference in incretin system among various ethnicities. This study is carried out to study the effect of dipeptidyl-peptidase IV (DPPIV) inhibitors in prediabetes and T2DM patients who have different levels of GLP-1 and to determine the effect on glycemic profiles, insulin resistance/sensitivity, beta-cell functon.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2021-03-01
- Completion
- 2021-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Linagliptin | Small molecule | 5 mg | — |